Simplify Asset Management Inc. Invests $612,000 in Palisade Bio, Inc. $PALI

Simplify Asset Management Inc. purchased a new stake in Palisade Bio, Inc. (NASDAQ:PALI) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 350,000 shares of the company’s stock, valued at approximately $612,000. Simplify Asset Management Inc. owned about 0.21% of Palisade Bio at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of PALI. Creek Drive Management Group LLC purchased a new position in Palisade Bio during the 4th quarter worth $723,000. Caitong International Asset Management Co. Ltd acquired a new position in Palisade Bio in the fourth quarter valued at $81,000. Seven Fleet Capital Management LP purchased a new stake in shares of Palisade Bio in the fourth quarter valued at about $770,000. Virtu Financial LLC purchased a new stake in shares of Palisade Bio in the fourth quarter valued at about $28,000. Finally, XTX Topco Ltd boosted its stake in shares of Palisade Bio by 53.8% during the fourth quarter. XTX Topco Ltd now owns 21,669 shares of the company’s stock worth $51,000 after buying an additional 7,584 shares during the period. Institutional investors and hedge funds own 11.79% of the company’s stock.

Palisade Bio Price Performance

Shares of NASDAQ:PALI opened at $2.10 on Friday. Palisade Bio, Inc. has a 52 week low of $0.53 and a 52 week high of $2.85. The company has a 50-day moving average price of $1.92 and a 200 day moving average price of $1.91. The company has a market cap of $364.52 million, a P/E ratio of -2.08 and a beta of 1.50.

Palisade Bio (NASDAQ:PALI) last released its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Analysts expect that Palisade Bio, Inc. will post -0.25 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on PALI shares. Wall Street Zen lowered Palisade Bio from a “hold” rating to a “sell” rating in a report on Saturday, June 27th. HC Wainwright reaffirmed a “buy” rating and set a $2.00 price objective on shares of Palisade Bio in a research note on Tuesday. Oppenheimer set a $7.00 price objective on Palisade Bio in a research report on Tuesday. LADENBURG THALM/SH SH upgraded Palisade Bio to a “strong-buy” rating in a research note on Thursday, June 25th. Finally, Weiss Ratings raised Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $8.83.

About Palisade Bio

Palisade Bio, Inc is a clinical?stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll?like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.